Skip to main content Accessibility help
×
Home

Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up

  • M. R. H. ROUSHAN (a1), M. MOHAMMADPOUR (a1), M. BAIANY (a1), S. SOLEIMANI (a2) and A. BIJANI (a1)...

Summary

To determine the time to appearance of antibody against hepatitis B surface antigen (anti-HBs) after clearance of hepatitis B surface antigen (HBsAg) in chronically infected individuals, we followed up 3963 cases with positive antibody against hepatitis B e antigen (anti-HBe) from 1991 to 2014. Of these, 101 (67 males, 34 females) lost HBsAg. These serocleared cases were checked every 6-month interval regarding HBsAg, anti-HBs, liver function tests, and liver sonography. Hepatitis B virus DNA was assessed at the time of seroclearance or the appearance of anti-HBs. The mean age of these patients at entry to this study was 34·4 ± 13 years. The mean follow-up duration until seroclearance of HBsAg was 6·6 ± 4·3 years. After the mean follow-up of 43·7 ± 45 months, anti-HBs appeared in 64 (63·4%) cases. The cumulative probabilities of anti-HBs appearance for 2, 5 and 10 years were 24·3%, 58% and 78·2%, respectively. The appearance of anti-HBs was associated with age ⩾35 years and seroclearance of HBsAg (hazard ratio 1·96, 95% confidence interval 1·32–3·38, P = 0·016) but not with sex. The results show that anti-HBs may develop in 78·2% of cases within 10 years of HBsAg clearance. Age ⩾35 years at HBsAg loss was associated with earlier development of anti-HBs.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Dr M. R. H. Roushan, Infectious Diseases and Tropical Medicine Research Centre, Babol University of Medical Sciences, Babol 4717641367, Iran. (Email: hagar2q@yahoo.ca)

References

Hide All
1. Sorrell, MF, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Annals of Internal Medicine 2009; 150: 104110.
2. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatology 2004; 11: 97107.
3. Papatheodoridis, G, et al. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012; 57: 167185.
4. Villa, E, et al. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Digestive and Liver Disease 2011; 43S: S8S14.
5. McMahan, BJ, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Annals of Internal Medicine 2001; 135: 759768.
6. Kim, JH, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology 2008; 55: 578581.
7. Simonetti, J, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 15311537.
8. Arase, Y, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. American Journal of Medicine 2006; 119: e916.
9. Ahn, SH, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. Journal of Hepatology 2005; 42: 188194.
10. Chen, YC, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 10841089.
11. Chu, CM, Liaw, YF. HBsAg seroclearance in asymptomatic carriers of high endemic area: appreciably high rates during a long term follow up. Hepatology 2007; 45: 11871192.
12. Liaw, YF, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection:a prospective study. Hepatology 1991; 13: 627631.
13. Thio, CL, Hawkins, C. Hepatitis B virus and hepatitis delta virus. In: Bennett, JE, Dolin, R, Blaser, MJ, eds. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease, 18th edn. Canada: Elsevier Saunders, 2015, pp. 18151839.
14. Fattovich, G, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. American Journal of Gastroenterology 1998; 93: 896900.
15. Yuen, MF, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virology, histological and clinical aspects. Hepatology 2004; 39: 16941701.
16. Huo, TI, et al. Seroclearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1999; 28: 231236.
17. Draelos, M, et al. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. Journal of the American Medical Association 1987; 258: 11931195.
18. Manno, M, et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756763.
19. Chen, YC, et al. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clinical Gastroenterology and Hepatology 2012; 10: 297302.
20. Kim, GA, et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. Journal of Hepatology 2014; 62: 10921099.
21. Yuen, MF, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 11921199.
22. Ferreira, SC, et al. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Annals of Hepatology 2014; 13: 762770.
23. Liu, J, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63: 1648–57.
24. Adachi, H, et al. Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology 1992; 16: 13341337.

Keywords

Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up

  • M. R. H. ROUSHAN (a1), M. MOHAMMADPOUR (a1), M. BAIANY (a1), S. SOLEIMANI (a2) and A. BIJANI (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed